Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Obesity Surgery|April 8, 2016
Publication Trends in Bariatric Surgery: a Bibliometric StudyYohann Dabi, Lauren Darrigues, Sandrine Katsahian, et al.
NPJ Digital Medicine|August 10, 2022
Interactive exploration of a global clinical network from a large breast cancer cohortNadir Sella, Anne-Sophie Hamy, Vincent Cabeli, et al.
Annales De Chirurgie Plastique Et Esthetique|November 13, 2025
[Indications for total mastectomy with immediate breast reconstruction in oncology: Surgical strategies tailored to breast morphology and adjuvant treatments]Lauren Darrigues, Fabien Reyal, Jean-Philippe Binder, et al.
Journal of Extracellular Biology|June 28, 2024
Circulating extracellular vesicles provide valuable protein, but not DNA, biomarkers in metastatic breast cancerMercedes Tkach, Caroline Hego, Marc Michel, et al.
Plos One|December 21, 2017
Incidence of inflammatory breast cancer in patients with clinical inflammatory breast symptomsYohann Dabi, Lauren Darrigues, Kelly Pons, et al.
Plastic and Reconstructive Surgery|April 3, 2025
The impact of fat graft reconstructive surgery on prognosis in young women with breast cancer: a study from the French insurance databasesEnora Laas, Thomas Gaillard, Benoit Couturaud, et al.
Annals of Surgical Oncology|January 6, 2026
Outcomes of Second Breast-Conserving Surgery Without Reirradiation for Breast Tumor RecurrenceThomas Gaillard, Arnaud Beddok, Yousrah Baadj, et al.
Cancers|January 27, 2021
HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab RegimensEnora Laas, Arnaud Bresset, Jean-Guillaume Féron, et al.
Bulletin Du Cancer|February 21, 2025
[Prophylactic breast surgery in high-risk breast cancer patients]Lauren Darrigues, Thomas Gaillard, Jonathan Sabah, et al.
British Journal of Cancer|January 27, 2024
Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclibThomas Gaillard, Jeanne Piketty, Jean-Guillaume Feron, et al.
Pageof 3